

DRUG ALERT

CLASS 4 MEDICINES DEFECT INFORMATION

Caution in Use

Distribute to Pharmacy/Wholesaler Level

Dear Healthcare Professional

Accord Healthcare Limited

Rosuvastatin 5 mg film-coated tablets

PL 20075/0402

Batch Number	Expiry Date	Pack Size	First Distributed
P2102389	03/2023	28	24-06-2022

Rosuvastatin 10 mg film-coated tablets

PL 20075/0403

Batch Number	Expiry Date	Pack Size	First Distributed
P2103803	04/2023	28	28-06-2022

Rosuvastatin 20 mg film-coated tablets

PL 20075/0404

Batch Number	Expiry Date	Pack Size	First Distributed
P2104132	05/2023	28	28-06-2022

Active Pharmaceutical Ingredient: Rosuvastatin calcium

Brief description of the problem

Further to a previous defect notification, <https://www.health-ni.gov.uk/sites/default/files/publications/health/doh-phc-23-2021.pdf> Accord Healthcare have informed us of an error with the patient information leaflets (PILs) that have been packaged in the above additional batches of products. These were an older version of the PIL which did not include the most up to date safety information.

Accord Healthcare have confirmed that this issue impacts 29086 packs across the three different batches mentioned. The MHRA have confirmed with Accord Healthcare that all other packs of the above batches on hold at the manufacturer will not be distributed.

The information missing from the PILs are as below:

Section 2 Other medicines and Rosuvastatin tablets:

Tell your doctor if you are taking any of the following:



Regorafenib (used to treat cancer), any of the following drugs used to treat viral infections, including HIV or hepatitis C infection, alone or in combination (please see Warnings and precautions): atazanavir, ombitasvir, paritaprevir, dasabuvir, velpatasvir, grazoprevir, elbasvir, glecaprevir, pibrentasvir.

Section 4 Possible side effects:

Stop taking Rosuvastatin tablets and talk to your doctor immediately

- If you experience muscle rupture
- If you have lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).

Rosuvastatin tablets may cause the following possible side effects:

Rare (may affect up to 1 in 1,000 people)

- Severe allergic reaction – signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). If you think you are having an allergic reaction, then stop taking Rosuvastatin tablets and seek medical help immediately
- Muscle damage in adults – as a precaution, stop taking Rosuvastatin tablets and talk to your doctor immediately if you have any unusual aches or pains in your muscles which go on for longer than expected
- Lupus-like disease syndrome (including rash, joint disorders and effects on blood cells).

Advice for healthcare professionals

There is no risk to product quality as a result of this issue, therefore the affected batches are not being recalled. Healthcare professionals are advised to exercise caution when dispensing the product and where possible, provide an updated PIL. The updated PIL is available via the MHRA website:

[Rosuvastatin 5 mg film-coated tablets-PIL](#)

[Rosuvastatin 10 mg film-coated tablets-PIL](#)

[Rosuvastatin 20 mg film-coated tablets-PIL](#)

Accord Healthcare Limited have confirmed that all future batches will contain the updated PIL and that upon request they will send hard copies by post of the updated PIL to wholesalers and pharmacies, so that any remaining stock in the dispensary can be supplemented with the updated PIL information.

Further Information

For more information or medical information queries, please contact: Accord Medical Information Department on 01271 385257, email- medinfo@accord-healthcare.com



For stock control queries, please contact: Accord- Customer Services Team on 0800 373573

For updated PIL requests please contact Email: contact@accord-healthcare.com Phone: 01271 385200

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice.

RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter.

TO ALL CHEMISTS, DOCTORS ON THE LISTS

Pharmaceutical Services
2 Franklin Street
BELFAST
BT2 8DQ

Telephone No. 028 9536 0333

17th August 2022

Pharmaceutical website: <http://www.hscbusiness.hscni.net>